jlzybio.com - Multiplikator nilai perusahaan marang pendapatan ZYBT

Limited pricing power in China's veterinary drug sector determines the EV/Sales trend, where the parameter value equals 5774.82. This price action relies on the number of new licenses and R&D expenditures. The critical importance of biosafety ensures stable demand, although revenue correlates with livestock population cycles. This chart objectively demonstrates the ratio of business value to sales, warning of the risks of entering at local highs for Zhengye Biotechnology (ZYBT).
ZYBT (jlzybio.com): rincian analitis lan laporan miturut indikator

Zhengye Biotechnology (ZYBT) ensures agricultural biosafety through the production of veterinary vaccines and complex cold-chain logistics. This indicator compares the total enterprise value to sales volume, excluding the impact of debt load. The metric captures the long-term capitalization-to-revenue ratio as a fundamental coordinate axis. Sharp deviations in the EV/Sales ratio signal asset overvaluation. Investors should interpret such spikes as a correction risk during a phase shift.